Raymond E. Moellering, PhD (Damon Runyon Fellow '11-'13), The Scripps Research Institute, La Jolla, California
Dr. Moellering is interested in understanding the link between alteration of metabolic pathways and corresponding protein modifications that occur in cancer cells. In addition, he is investigating whether cancer cells use small molecule signaling, known as quorum-sensing, to communicate and thus control tumor initiation, growth and metastasis. His goal is to provide insights into many aspects of tumor progression and to potentially identify new opportunities for therapeutic intervention.
Nathan D. Thomsen, PhD (Damon Runyon Fellow '11-'13), University of California, San Francisco, California
Dr. Thomsen is studying the molecular interactions that are required for specific signaling pathways in the cell. In cancer cells, these signaling pathways are often disrupted or misregulated. Using sophisticated new techniques he has developed, he will "capture and trap" proteins in real time, as they are signalingsimilar to a video freeze-frame. He plans to then engineer antibodies that will specifically target and inhibit these pathways, which can be used to learn more about the molecular mechanisms underlying signaling and may eventually be developed into therapeutics for cancer and other diseases.
Cole Trapnell, PhD (Damon Runyon Fellow '11-'14), Harvard University, Cambridge, Massachusetts'/>"/>
|Contact: Yung S. Lie, Ph.D.|
Damon Runyon Cancer Research Foundation